GlassScriptPhysician profile
Pankaj Kakkar
NPI 1912278615
$1,820.38
in general payments reported to CMS, 2019-2025
22 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.30 · 2020: $30.89 · 2021: $253 · 2022: $402 · 2023: $292 · 2024: $509 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,086.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $338.12 | 2021-2025 | Vyepti, Rexulti |
| Abbvie INC. | $268.88 | 2022-2025 | |
| Lilly USA, LLC | $265.38 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Sk Life Science, INC. | $246.35 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $108.85 | 2021-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $76.84 | 2021-2025 | Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $68.95 | 2021-2025 | Qelbree |
| Jazz Pharmaceuticals INC. | $53.93 | 2022-2024 | |
| Neurelis, INC. | $52.96 | 2022-2024 | Valtoco |
| Pfizer INC. | $48.18 | 2023-2025 | |
| Harmony Biosciences LLC | $46.91 | 2021-2023 | Wakix |
| Biohaven Pharmaceutical Holding Company LTD. | $40.93 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $39.42 | 2025 | Rexulti |
| Greenwich Biosciences, INC. | $28.68 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $26.99 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $18.34 | 2025 | Brekiya |
| Aquestive Therapeutics, INC. | $17.29 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.58 | 2020 | |
| Impel Pharmaceuticals INC. | $15.54 | 2022 | |
| Aucta Pharmaceuticals, INC. | $14.02 | 2024 | Motpoly Xr |
| Collegium Pharmaceutical, INC. | $13.67 | 2022 | |
| Corium, LLC | $13.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Kakkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.